Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Genmab A/S ADR (NQ: GMAB ) 24.32 +0.20 (+0.83%) Streaming Delayed Price Updated: 12:53 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Genmab A/S ADR < Previous 1 2 3 4 5 6 Next > Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session September 23, 2024 Via Benzinga NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying. September 17, 2024 GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals. Via Chartmill Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. September 16, 2024 Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. Via Chartmill Expert Ratings For Genmab September 09, 2024 Via Benzinga NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. September 03, 2024 Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock? Via Chartmill NASDAQ:GMAB is showing good growth, while it is not too expensive. August 26, 2024 GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing. Via Chartmill Decoding 10 Analyst Evaluations For Genmab August 20, 2024 Via Benzinga Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock? August 05, 2024 Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. Via Chartmill What 8 Analyst Ratings Have To Say About Genmab August 01, 2024 Via Benzinga What 8 Analyst Ratings Have To Say About Genmab July 15, 2024 Via Benzinga On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session August 13, 2024 Via Benzinga GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024 August 08, 2024 GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products August 05, 2024 BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... Via Benzinga Exposures COVID-19 While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. August 05, 2024 While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. Via Chartmill Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. July 15, 2024 GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably. Via Chartmill NASDAQ:GMAB, an undervalued stock with good fundamentals. July 01, 2024 GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. Via Chartmill 10 Analysts Assess Genmab: What You Need To Know June 20, 2024 Via Benzinga What 9 Analyst Ratings Have To Say About Genmab May 20, 2024 Via Benzinga AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway June 27, 2024 The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. Via Benzinga Exposures Product Safety 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. Via InvestorPlace Despite its growth, NASDAQ:GMAB remains within the realm of affordability. June 21, 2024 Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. Via Chartmill 7 Stocks That Could Safely 10X by 2030 June 06, 2024 Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align. Via InvestorPlace Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session May 24, 2024 Via Benzinga NASDAQ:GMAB is showing good growth, while it is not too expensive. May 02, 2024 Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB). Via Chartmill Decoding 9 Analyst Evaluations For Genmab April 30, 2024 Via Benzinga NASDAQ:GMAB is not too expensive for the growth it is showing. April 11, 2024 Via Chartmill 7 Biotech Stocks That Could Breathe New Life Into Your Portfolio May 20, 2024 Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. Via InvestorPlace GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024 May 02, 2024 GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market April 25, 2024 The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. Via Investor's Business Daily ProfoundBio Discovers The Joys Of Having A Wealthy Owner April 08, 2024 Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a... Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
